KUALA LUMPUR, Jan 30 – Rex Clements has been appointed Chief Executive Officer (CEO) of Centrient Pharmaceuticals, the global leader in the production and commercialisation of sustainable antibiotics, next-generation statins and anti-fungals.
His appointment is effective March 16. He has the mandate to drive and execute the strategy defined by the Supervisory Board of Directors and the Executive Committee, pursuing the growth trajectory the company has already set in motion.
Clements takes over from Karl Rotthier who has stepped down as CEO after having built a highly successful company over the last 10 years, and managing a smooth transition to the new ownership under Bain Capital, according to a statement.
Rotthier, having led the company for almost a decade and established Centrient in a unique position, has decided that Centrient Pharmaceuticals be led by a new CEO who will bring fresh perspectives for the next phase of growth.
Meanwhile, Clements brings more than two decades of experience gained across multiple assignments in the industry.
-- BERNAMA
No comments:
Post a Comment